1,099 results

#50476-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-hM3D(Gq)-mCherry (#50476). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM3D(Gq)-mCherry plasmid DNA. CaMKIIa-driven hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 26, 2021

Academic Institutions and Nonprofits only

#100835-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 (#100835). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

May 11, 2018

Academic Institutions and Nonprofits only

#191707-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP12237 - pAAV-AiE0452h-minBG-SYFP2-WPRE3-BGHpA (Alias: CN2237) (#191707). In addition to the viral particles, you will also receive purified AiP12237 - pAAV-AiE0452h-minBG-SYFP2-WPRE3-BGHpA (Alias: CN2237) plasmid DNA. minBG-driven expression of SYFP2 in striatal indirect pathway medium spiny neurons (D2-MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#114469-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-CaMKIIa-mCherry (#114469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-mCherry plasmid DNA. CamKIIa-driven expression of mCherry. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 16, 2024

Academic Institutions and Nonprofits only

#55645-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn Con/Fon hChR2(H134R)-EYFP (#55645). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon hChR2(H134R)-EYFP plasmid DNA. Synapsin-driven, Cre-dependent and Flp-dependent Channelrhodopsin-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 23, 2018

Academic Institutions and Nonprofits only

#58880-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Syn-ChR2(H134R)-GFP (#58880). In addition to the viral particles, you will also receive purified pAAV-Syn-ChR2(H134R)-GFP plasmid DNA. Humanized channelrhodopsin H134R mutant fused to GFP, under the control of the Synapsin promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Boyden et al Nat Neurosci. 2005 Sep . 8(9):1263-8.

June 20, 2017

Academic Institutions and Nonprofits only

#140554-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_DA2h (#140554). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_DA2h plasmid DNA. Synapsin-driven expression of high-affinity GRAB_DA2h dopamine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 9, 2021

Academic Institutions and Nonprofits only

#208717-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-GRAB_g5-HT3.0 (#208717). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_g5-HT3.0 plasmid DNA. Synapsin-driven expression of GRAB_g5-HT3.0 sensor. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Deng et al Nat Methods. 2024 Apr;21(4):692-702. doi

Sept. 22, 2025

Academic Institutions and Nonprofits only

#84446-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

March 18, 2024

Academic Institutions and Nonprofits only

#131002-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Nov. 29, 2021

Academic Institutions and Nonprofits only

#172922-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-jGCaMP8m-P2A-mRuby3 (#172922). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-jGCaMP8m-P2A-mRuby3 plasmid DNA. hSyn-driven expression of jGCaMP8m in axons with cytosolic expression of mRuby3. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Aug. 24, 2023

Academic Institutions and Nonprofits only

#191706-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP13044 - pAAV-AiE0779m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3044) (#191706). In addition to the viral particles, you will also receive purified AiP13044 - pAAV-AiE0779m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3044) plasmid DNA. SYFP2-expression in striatal direct pathway medium spiny neurons (D1-MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

July 15, 2024

Academic Institutions and Nonprofits only

#100835-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 (#100835). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

May 11, 2018

Academic Institutions and Nonprofits only

#137152-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-NpHR3.3-EYFP (#137152). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-NpHR3.3-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of NpHR3.3-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 25, 2021

Academic Institutions and Nonprofits only

#100844-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAG.GCaMP6s.WPRE.SV40 (#100844). In addition to the viral particles, you will also receive purified pAAV.CAG.GCaMP6s.WPRE.SV40 plasmid DNA. CAG-driven GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

March 16, 2018

Academic Institutions and Nonprofits only

#105530-AAV1

Ready-to-use AAV1 particles produced from pAAV.CMV.PI.EGFP.WPRE.bGH (#105530). In addition to the viral particles, you will also receive purified pAAV.CMV.PI.EGFP.WPRE.bGH plasmid DNA. CMV-driven EGFP control. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

March 26, 2019

Academic Institutions and Nonprofits only

#213943-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe3_GCaMP6f (#213943). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the PV+ basket cell-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#83896-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hDlx-GiDREADD-dTomato-Fishell-5 (#83896). In addition to the viral particles, you will also receive purified pAAV-hDlx-GiDREADD-dTomato-Fishell-5 plasmid DNA. hDlx-driven expression of Gi-DREADD and nuclear localized dTomato (physically separate). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

June 1, 2020

Academic Institutions and Nonprofits only

#26976-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn-hChR2(H134R)-mCherry (#26976). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-mCherry plasmid DNA. Synapsin-driven, humanized channelrhodopsin H134R mutant, fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Oct. 9, 2019

Academic Institutions and Nonprofits only

#135632-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-GCaMP6f (#135632). In addition to the viral particles, you will also receive purified pAAV-S5E2-GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Nov. 11, 2020

Academic Institutions and Nonprofits only